Zilovertamab (UC-961) is a humanised monoclonal antibody against ROR1 that blocks Wnt5a-induced ROR1 signalling[1].
Zilovertamab (25 and 50 µg/mL; 72 h) inhibits high-grade serous ovarian cancer (HGSOC) cell proliferation[1].
Zilovertamab (50 µg/mL; 72 h) down-regulates ROR1 expression levels in CaOV3 at the transcriptional level[1].
Cell Proliferation Assay[1]
| Cell Line: | CaOV3, CaOV3CisR, PEO1, and PEO4 cells |
| Concentration: | 25 and 50 µg/mL |
| Incubation Time: | 72 hours |
| Result: | Reduced the proliferation of CaOV3, CaOV3CisR and PEO1. |
Western Blot Analysis[1]
| Cell Line: | CaOV3, CaOV3CisR, PEO1, and PEO4 cells |
| Concentration: | 50 µg/mL |
| Incubation Time: | 72 hours |
| Result: | Down-regulated ROR1 expression levels in CaOV3 at the transcriptional level. |